BlackRock Global Funds - World Healthscience Fund A10 USDRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | -3.6 | 7.8 | |
+/-Cat | - | - | - | -0.5 | 4.1 | |
+/-B’mrk | - | - | - | -1.0 | 0.4 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 22/11/2024 | USD 9.97 | |
Day Change | 2.18% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU2533724352 | |
Fund Size (Mil) 31/10/2024 | USD 14268.29 | |
Share Class Size (Mil) 22/11/2024 | USD 7.32 | |
Max Initial Charge | - | |
Ongoing Charge 19/04/2024 | 1.81% |
Investment Objective: BlackRock Global Funds - World Healthscience Fund A10 USD |
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Xiang Liu 01/06/2020 | ||
Erin Xie 01/04/2011 | ||
Inception Date 26/10/2022 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BlackRock Global Funds - World Healthscience Fund A10 USD | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 7.95 |
UnitedHealth Group Inc | Healthcare | 7.28 |
AbbVie Inc | Healthcare | 5.28 |
Boston Scientific Corp | Healthcare | 4.78 |
Novo Nordisk AS Class B | Healthcare | 4.66 |
Increase Decrease New since last portfolio | ||
BlackRock Global Funds - World Healthscience Fund A10 USD |